To estimate the intraocular pressure (IOP)-lowering effect of prostaglandin analogs (PGAs) administered in combination with β-blockers.
Methods:
We searched the Medline and Embase databases for randomized trials comparing topical therapies with PGAs and timolol administered as monotherapy (Mt), or in fixed (FC) or unfixed combinations (UC) to patients with glaucoma or ocular hypertension. The efficacy endpoint was the mean difference (MeD) in the reduction in IOP from baseline; the tolerability endpoint was the incidence of hyperemia.
Results:
The 18 eligible trials involved 23 comparisons of FC versus Mt, and 5 of FC versus UC. The FCs were less efficacious than UCs (MeD: 0.69, 95% CI: 0.29 to 1.08). In comparison with timolol Mt, the latanoprost/timolol FC led to a greater IOP reduction (MeD: −2.74, 95% CI: −3.24 to −2.23) than the bimatoprost/timolol FC (MeD: −1.49, 95% CI: −1.86 to −1.12) or the travoprost/timolol FC (MeD: −1.93, 95%CI: −2.98 to −0.88). The FCs led to a lower hyperemia risk than UCs [relative risk (RR): 0.70, 95% CI: 0.43 to 1.14] and PGA Mt (RR: 0.61, 95% CI: 0.53 to 0.70).
Conclusions:
FCs are more efficacious than their individual components, but less efficacious than their respective UCs. FCs lead to a lower hyperemia risk than UCs and their respective PGA Mts.
Get full access to this article
View all access options for this article.
References
1.
KassM.A., HeuerD.K., HigginbothamE.J.et al.The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol., 120:701–13discussion 829–8302002.
2.
ColemanA.L., MigliorS.Risk factors for glaucoma onset and progression. Surv. Ophthalmol., 53,Suppl1:S3–S10. 2008.
3.
European GlaucomaSociety. Terminology and Guidelines for Glaucoma, 3rd. Editrice Dogma S.r.l: Italy, 2008.
4.
HigginbothamE.J.Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin. Ophthalmol., 4:1–9. 2010.
5.
OlthoffC.M., SchoutenJ.S., van de BorneB.W., WebersC.A.Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology, 112:953–961. 2005.
6.
PatelS.C., SpaethG.L.Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic. Surg., 26:233–236. 1995.
7.
SleathB., RobinA.L., CovertD., ByrdJ.E., TudorG., SvarstadB.Patient-reported behavior and problems in using glaucoma medications. Ophthalmology, 113:431–436. 2006.
8.
HolloG., ChiselitaD., PetkovaN.et al.The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Eur. J. Ophthalmol., 16:816–823. 2006.
9.
O'ConnorD.J., MartoneJ.F., MeadA.Additive intraocular pressure lowering effect of various medications with latanoprost. Am. J. Ophthalmol., 133:836–837. 2002.
10.
ReisR., QueirozC.F., SantosL.C., AvilaM.P., MagachoL.A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Clin. Ther., 28:552–559. 2006.
11.
VerhagenA.P., de VetH.C., de BieR.A.et al.The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J. Clin. Epidemiol., 51:1235–1241. 1998.
12.
HigginsJ.P.T., GreenS.Cochrane Handbook for Systematic Reviews of Interventions. Chichester, England: John Wiley & Sons Ltd., 2010; 485–488.
13.
DerSimonianR., KackerR.Random-effects model for meta-analysis of clinical trials: an update. Contemp. Clin. Trials, 28:105–114. 2007.
14.
HigginsJ.P., ThompsonS.G., DeeksJ.J., AltmanD.G.Measuring inconsistency in meta-analyses. BMJ, 327:557–560. 2003.
15.
SterneJ.A., EggerM.Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J. Clin. Epidemiol., 54:1046–1055. 2001.
16.
KonstasA.G., MikropoulosD., HaidichA.B., NtamposK.S., StewartW.C.Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. Br. J. Ophthalmol., 93:481–485. 2009.
17.
HigginbothamE.J., OlanderK.W., KimE.E., GrundenJ.W., KwokK.K., TresslerC.S.Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch. Ophthalmol., 128:165–172. 2010.
18.
DiestelhorstM., AlmegardB.Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma. Graefes Arch. Clin. Exp. Ophthalmol., 236:577–581. 1998.
19.
HigginbothamE.J., FeldmanR., StilesM., DubinerH.Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch. Ophthalmol., 120:915–922. 2002.
20.
PfeifferN.A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch. Clin. Exp. Ophthalmol., 240:893–899. 2002.
21.
DiestelhorstM., LarssonL.I.A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br. J. Ophthalmol., 88:199–203. 2004.
22.
BarnebeyH.S., Orengo-NaniaS., FlowersB.E.et al.The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am. J. Ophthalmol., 140:1–7. 2005.
23.
HughesB.A., BacharachJ., CravenE.R.et al.A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J. Glaucoma., 14:392–399. 2005.
24.
KonstasA.G., BoboridisK., TzetziD., KallinderisK., JenkinsJ.N., StewartW.C.Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch. Ophthalmol., 123:898–902. 2005.
25.
SchumanJ.S., KatzG.J., LewisR.A.et al.Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol., 140:242–250. 2005.
26.
DiestelhorstM., LarssonL.I.A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology, 113:70–76. 2006.
27.
KonstasA.G., LakeS., EconomouA.I., KaltsosK., JenkinsJ.N., StewartW.C.24-Hour control with a latanoprost-timolol fixed combination vs timolol alone. Arch. Ophthalmol., 124:1553–1557. 2006.
28.
BrandtJ.D., CantorL.B., KatzL.J., BatoosinghA.L., ChouC., BossowskaI.Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J. Glaucoma., 17:211–216. 2008.
29.
KonstasA.G., PikilidouM.I., TsironiS.et al.24-hour intraocular pressure and blood pressure levels with latanoprost/timolol fixed combination versus timolol. Curr. Eye Res., 34:369–377. 2009.
30.
LewisR.A., GrossR.L., SallK.N., SchiffmanR.M., LiuC.C., BatoosinghA.L.The safety and efficacy of bimatoprost/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J. Glaucoma., 19:424–426. 2010.
31.
ZhaoJ.L., GeJ., LiX.X.et al.Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension. BMC Ophthalmol., 11:23. 2011.
32.
PalmbergP., KimE.E., KwokK.K., TresslerC.S.A 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy. Eur. J. Ophthalmol., 20:708–718. 2010.
33.
TabetR., StewartW.C., FeldmanR., KonstasA.G.A review of additivity to prostaglandin analogs: fixed and unfixed combinations. Surv. Ophthalmol., 53,Suppl1:S85–S92. 2008.
34.
AptelF., CucheratM., DenisP.Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur. J. Ophthalmol., 22:5–18. 2012.
35.
ParanhosA., MendoncaM, SilvaM.J.et al.Hyperemia reduction after administration of a fixed combination of bimatoprost and timolol maleate to patients on prostaglandin or prostamide monotherapy. J. Ocul. Pharmacol. Ther., 26:611–615. 2010.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
